Kymriah
Israeli Oncologists Show Point-of-Care CAR T Cells Have Comparable Efficacy to Yescarta, Kymriah
Premium
Lymphoma patients better tolerated the CAR T-cell therapy manufactured on-site at the Sheba Medical Center than they did the commercially available options.
Meta-Analysis Questions FDA Warning on Secondary Cancer Risks With CAR T-Cell Therapies
Researchers analyzed two dozen studies and found similar rates of second primary cancers in patients receiving CAR T-cell and standard therapies.
FDA Requires Boxed Warning of Secondary Cancer Risk for Autologous CAR T-Cell Therapies
The requirement comes after FDA investigated data showing patients developed secondary T-cell malignancies after CD19- and BCMA-directed CAR T-cell therapies.
Cell Therapy Research Consortia Responds to FDA's CAR T-Cell Therapy Warning
Experts in gene and cell therapy, transplantation, and immunotherapy say patients should continue to receive CAR T-cell therapy while the investigation is underway.
Some patients whose CLL turned into lymphoma had durable responses on autologous cell therapies, according to a retrospective analysis featured at the ASH annual meeting.